The purpose of this study is to see if an experimental vaccine called CH505 TF chTrimer is safe and well tolerated in people living with human immunodeficiency virus (HIV) and to see if it will help the body's immune system respond to HIV.
This study is looking to see if an investigational anti-HIV vaccine is safe and well-tolerated in people living with HIV. The study is also trying to find out if the vaccine can help the immune system work against HIV. It is given as one injection, similar to a flu shot, in each upper arm five times over one year (ten injections total). Study participants will have a 2 in 3 chance of receiving the active vaccine and a 1 in 3 chance of getting a placebo (looks like the vaccine but contains no active medicine). A computer will assign you to one of the groups and neither you nor the study staff will know which group you are assigned to.
-Persons aged 18 years and older living with HIV-1 -On stable HIV treatment for a minimum of 2 years -Current CD4+ cell count ≥200 cells/mm3 -HIV viral load of <50 copies/mL currently and for the past year -No current Hepatitis B or C infection -Agree to use effective birth control during most of study if possible to become pregnant or cause a pregnancy
Principal Investigator